First National Corp Halozyme Therapeutics, Inc. Transaction History

First National Corp

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2019 Jul 30, 2019	SELL	$14.75 - $17.26 $25,222 - $29,514	-1,710 Closed	0 $0
Q4 2018 Jun 12, 2019	BUY	$13.33 - $18.66 $22,794 - $31,908	1,710 New	1,710 $25,000

550

124M

668K

259K

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $8.38B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

Get notified when there are updates to the investment portfolio of First National Corp , based on Form 13F filings with the SEC.

Stay updated on First National Corp with notifications on news.